Global Inhaled Nitric Oxide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Inhaled Nitric Oxide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Inhaled Nitric Oxide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Inhaled Nitric Oxide market is projected to reach US$ 1906.6 million in 2034, increasing from US$ 1084 million in 2022, with the CAGR of 8.3% during the period of 2024 to 2034. Demand from Near-term and Pre-term Infants PPHN and Children and Adult ARDS are the major drivers for the industry.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Inhaled Nitric Oxide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
Segment by Type
800 ppm
100 ppm
Others
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Inhaled Nitric Oxide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Inhaled Nitric Oxide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Inhaled Nitric Oxide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Inhaled Nitric Oxide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Inhaled Nitric Oxide introduction, etc. Inhaled Nitric Oxide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Inhaled Nitric Oxide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Inhaled Nitric Oxide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Inhaled Nitric Oxide market is projected to reach US$ 1906.6 million in 2034, increasing from US$ 1084 million in 2022, with the CAGR of 8.3% during the period of 2024 to 2034. Demand from Near-term and Pre-term Infants PPHN and Children and Adult ARDS are the major drivers for the industry.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Inhaled Nitric Oxide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
Segment by Type
800 ppm
100 ppm
Others
Segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Inhaled Nitric Oxide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Inhaled Nitric Oxide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Inhaled Nitric Oxide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Inhaled Nitric Oxide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Inhaled Nitric Oxide introduction, etc. Inhaled Nitric Oxide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Inhaled Nitric Oxide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices